Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jussi Jaakko Saukkonen, M.D.

Title
Institution
Department
Address
Phone

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01HL062977 (SAUKKONEN, JUSSI J) Sep 30, 1999 - Jul 31, 2004
    NIH/NHLBI
    CHEMOKINES IN HOST RESPONSE TO MYCOBACTERIAL INFECTION
    Role: Principal Investigator
  2. R29HL053249 (SAUKKONEN, JUSSI J) Aug 1, 1994 - Jul 31, 1999
    NIH/NHLBI
    PATHOGENESIS OF HIV ALVEOLITIS AND ROLE OF A CD8 SUBSET
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Hedges KNC, Borisov AS, Saukkonen JJ, Scott NA, Hecker EJ, Bozeman L, Dukes Hamilton C, Kerrigan A, Bessler P, Moreno-Martinez A, Arevalo B, Goldberg SV. Nonparticipation reasons in a randomized international trial of a new latent tuberculosis infection regimen. Clin Trials. 2020 Feb; 17(1):39-51. PMID: 31690107.
    Citations:    
  2. Moro RN, Sterling TR, Saukkonen J, Vernon A, Horsburgh CR, Chaisson RE, Hamilton CD, Villarino ME, Goldberg S. Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial. Int J Tuberc Lung Dis. 2017 03 01; 21(3):286-296. PMID: 28087928.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  3. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016 10 01; 63(7):853-67. PMID: 27621353.
    Citations: 13     Fields:    Translation:HumansCellsPHPublic Health
  4. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016 10 01; 63(7):e147-e195. PMID: 27516382.
    Citations: 54     Fields:    Translation:HumansCellsPHPublic Health
  5. Moro RN, Borisov AS, Saukkonen J, Khan A, Sterling TR, Villarino ME, Scott NA, Shang N, Kerrigan A, Goldberg SV. Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada. Clin Infect Dis. 2016 06 01; 62(11):1390-1400. PMID: 26951571.
    Citations: 3     Fields:    Translation:Humans
  6. Jayakumar A, Vittinghoff E, Segal MR, MacKenzie WR, Johnson JL, Gitta P, Saukkonen J, Anderson J, Weiner M, Engle M, Yoon C, Kato-Maeda M, Nahid P. Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis. Tuberculosis (Edinb). 2015 Jul; 95(4):415-20. PMID: 26022314.
    Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
  7. Kane M, Korn B, Saukkonen J, McDonald C, Walsh C, Waters R, McLaughlin AM, Keane J. Barriers to accepting and completing latent tuberculosis infection treatment. Ir Med J. 2013 Jul-Aug; 106(7):200-4. PMID: 24218745.
    Citations: 1     Fields:    Translation:Humans
  8. Hales CM, Heilig CM, Chaisson R, Leung CC, Chang KC, Goldberg SV, Gordin F, Johnson JL, Muzanyi G, Saukkonen J, Vernon A, Villarino ME, Burman WJ. The association between symptoms and microbiologically defined response to tuberculosis treatment. Ann Am Thorac Soc. 2013 Feb; 10(1):18-25. PMID: 23509328.
    Citations: 7     Fields:    Translation:HumansCells
  9. Padayatchi N, Mac Kenzie WR, Hirsch-Moverman Y, Feng PJ, Villarino E, Saukkonen J, Heilig CM, Weiner M, El-Sadr WM. Lessons from a randomised clinical trial for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012 Dec; 16(12):1582-7. PMID: 23131255.
    Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
  10. Goswami ND, Gadkowski LB, Piedrahita C, Bissette D, Ahearn MA, Blain ML, Østbye T, Saukkonen J, Stout JE. Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study. BMC Public Health. 2012 Jun 21; 12:468. PMID: 22720842.
    Citations: 13     Fields:    Translation:Humans
  11. Lamunu D, Chapman KN, Nsubuga P, Muzanyi G, Mulumba Y, Mugerwa MA, Goldberg S, Bozeman L, Engle M, Saukkonen J, Mastranunzio S, Mayanja-Kizza H, Johnson JL. Reasons for non-participation in an international multicenter trial of a new drug for tuberculosis treatment. Int J Tuberc Lung Dis. 2012 Apr; 16(4):480-5. PMID: 22640513.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  12. Saukkonen JJ, Powell K, Jereb JA. Monitoring for tuberculosis drug hepatotoxicity: moving from opinion to evidence. Am J Respir Crit Care Med. 2012 Mar 15; 185(6):598-9. PMID: 22422902.
    Citations: 3     Fields:    Translation:Humans
  13. Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, Villarino ME, Weiner M, Benson C, Burman W. CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med. 2011 Oct 15; 184(8):972-9. PMID: 21737585.
    Citations: 24     Fields:    Translation:Humans
  14. O'Donnell MR, Coe A, Bliss C, Lee D, Tumilty S, Skolnik PR, Horsburgh CR, Cotton D, Saukkonen J. Acceptance of interferon-gamma release assay by a high-risk urban cohort. Int J Tuberc Lung Dis. 2011 Oct; 15(10):1334-9. PMID: 22283891.
    Citations:    Fields:    Translation:Humans
  15. Heilig CM, Chia D, El-Sadr WM, Hirsch-Moverman Y, Kenzie WR, Saukkonen J, Villarino ME, Padayatchi N. Justifying research risks in a clinical trial for treatment of multidrug-resistant tuberculosis. IRB. 2011 Jul-Aug; 33(4):10-7. PMID: 21932482.
    Citations: 1     Fields:    Translation:Humans
  16. Al Husseini AM, Lee HJ, Negrete J, Powelson S, Servi AT, Slocum AH, Saukkonen J. Design and Prototyping of a Low-Cost Portable Mechanical Ventilator. J Med Device. 2010 Jun 01; 4(2):027514. PMID: 32328214.
    Citations:    
  17. Saukkonen J. Challenges in reintroducing tuberculosis medications after hepatotoxicity. Clin Infect Dis. 2010 Mar 15; 50(6):840-2. PMID: 20156056.
    Citations: 1     Fields:    Translation:Humans
  18. Patel NR, Zhu J, Tachado SD, Zhang J, Wan Z, Saukkonen J, Koziel H. HIV impairs TNF-alpha mediated macrophage apoptotic response to Mycobacterium tuberculosis. J Immunol. 2007 Nov 15; 179(10):6973-80. PMID: 17982088.
    Citations: 34     Fields:    Translation:HumansCells
  19. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006 Oct 15; 174(8):935-52. PMID: 17021358.
    Citations: 170     Fields:    Translation:Humans
  20. Shieh FK, Snyder G, Horsburgh CR, Bernardo J, Murphy C, Saukkonen JJ. Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med. 2006 Sep 15; 174(6):717-21. PMID: 16809632.
    Citations: 27     Fields:    Translation:HumansPHPublic Health
  21. Parsyan AE, Saukkonen J, Barry MA, Sharnprapai S, Horsburgh CR. Predictors of failure to complete treatment for latent tuberculosis infection. J Infect. 2007 Mar; 54(3):262-6. PMID: 16772095.
    Citations: 9     Fields:    Translation:Humans
  22. Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B, Khan A, Burman WJ. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med. 2004 Dec 15; 170(12):1360-6. PMID: 15477492.
    Citations: 38     Fields:    Translation:HumansCellsCTClinical Trials
  23. Saukkonen J. Rifampin and pyrazinamide for latent tuberculosis infection: clinical trials and general practice. Clin Infect Dis. 2004 Aug 15; 39(4):566-8. PMID: 15356823.
    Citations:    Fields:    Translation:Humans
  24. Wilson KC, Saukkonen JJ. Acute respiratory failure from abused substances. J Intensive Care Med. 2004 Jul-Aug; 19(4):183-93. PMID: 15296619.
    Citations: 14     Fields:    Translation:HumansAnimals
  25. Jasmer RM, Snyder DC, Saukkonen JJ, Hopewell PC, Bernardo J, King MD, Kawamura LM, Daley CL. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial. Clin Infect Dis. 2004 Feb 01; 38(3):363-9. PMID: 14727206.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  26. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, King MD, Kawamura LM, Hopewell PC. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med. 2002 Oct 15; 137(8):640-7. PMID: 12379063.
    Citations: 28     Fields:    Translation:HumansCTClinical Trials
  27. Saukkonen JJ, Bazydlo B, Thomas M, Strieter RM, Keane J, Kornfeld H. Beta-chemokines are induced by Mycobacterium tuberculosis and inhibit its growth. Infect Immun. 2002 Apr; 70(4):1684-93. PMID: 11895930.
    Citations: 39     Fields:    Translation:HumansCells
  28. Jones BW, Heldwein KA, Means TK, Saukkonen JJ, Fenton MJ. Differential roles of Toll-like receptors in the elicitation of proinflammatory responses by macrophages. Ann Rheum Dis. 2001 Nov; 60 Suppl 3:iii6-12. PMID: 11890657.
    Citations: 34     Fields:    Translation:HumansAnimalsCells
  29. Saukkonen JJ, Tantri A, Berman J. Costimulation of CD28- T cells through CD3 and beta1-integrins induces a limited Th1 cytokine response. Scand J Immunol. 1999 Aug; 50(2):145-9. PMID: 10447918.
    Citations: 1     Fields:    Translation:HumansCells
  30. Mashikian MV, Tarpy RE, Saukkonen JJ, Lim KG, Fine GD, Cruikshank WW, Center DM. Identification of IL-16 as the lymphocyte chemotactic activity in the bronchoalveolar lavage fluid of histamine-challenged asthmatic patients. J Allergy Clin Immunol. 1998 Jun; 101(6 Pt 1):786-92. PMID: 9648706.
    Citations: 4     Fields:    Translation:HumansCells
  31. Saukkonen JJ, Furfaro S, Mahoney KM, Strieter RM, Burdick M, Wright EA, Kornfeld H, Berman JS. In vitro transendothelial migration of blood T lymphocytes from HIV-infected individuals. AIDS. 1997 Nov; 11(13):1595-601. PMID: 9365764.
    Citations: 2     Fields:    Translation:HumansCells
  32. Hendra KP, Saukkonen JJ. Erosion of the right mainstem bronchus by an esophageal stent. Chest. 1996 Sep; 110(3):857-8. PMID: 8797444.
    Citations: 3     Fields:    Translation:Humans
  33. Berman JS, Mahoney K, Saukkonen JJ, Masuyama J. Migration of distinct subsets of CD8+ blood T cells through endothelial cell monolayers in vitro. J Leukoc Biol. 1995 Sep; 58(3):317-24. PMID: 7665987.
    Citations: 2     Fields:    Translation:HumansCells
  34. Saukkonen JJ, Kornfeld H, Berman JS. Expansion of a CD8+CD28- cell population in the blood and lung of HIV-positive patients. J Acquir Immune Defic Syndr (1988). 1993 Nov; 6(11):1194-204. PMID: 8229654.
    Citations: 19     Fields:    Translation:HumansCells
  35. Hollmén A, Saukkonen J. Postoperative serum glutamic-oxalacetic transaminase and glutamic-pyruvic transaminase changes in biliary patients. Acta Anaesthesiol Scand. 1967; 11(4):393-400. PMID: 5597538.
    Citations:    Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Saukkonen's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (215)
Explore
_
Co-Authors (3)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.